News search

    E.g., 22/11/2024
    E.g., 22/11/2024
    Carlos Torroja, Jacob F. Bentzon, Paula Nogales, Laura Carramolino, Vanessa Cumbicus, Daniel Morales, Ana Dopazo, Verónica Labrador y Alberto Benguria
    Research
    1 Feb 2024
    Nature Cardiovascular Research: New approach to the design of therapies that enhance the effect of cholesterol-lowering drugs

    A study published in Nature Cardiovascular Research reveals smooth muscle-derived cells as a new target for reducing the size of atherosclerotic plaque. The results open up new avenues for the design of treatments to enhance the beneficial effect of cholesterol-lowering drugs
    Catarina Tristão Pereira, Enrique Lara Pezzi, Raquel Toribio Fernández, Borja Ibáñez, Valentín Fuster, Sergio Callejas, Marta Cortés Canteli, Ana Dopazo, Pilar Martín, Inés García Lunar e Irene Fernández Nueda.
    Research
    23 Jan 2024
    Circulation Research: APOE genetic variants linked to Alzheimer disease are also associated with the development of subclinical aterosclerosis

    The most potent genetic risk factor for Alzheimer disease, APOE4, is associated with an elevated risk of developing subclinical atherosclerosis in middle age, whereas the Alzheimer-protective variant of the same gene, APOE2, protects against subclinical atherosclerosis
    About the CNIC
    18 Jan 2024
    Don´t miss the new videos showcasing research at the CNIC
    Foto de grupo Jacardi
    About the CNIC
    29 Nov 2023
    CNIC and the i+12 Institute participate in the most ambitious EU project to reduce the burden of cardiovascular diseases and diabetes

    CNIC and the i+12 Institute co-lead one of the working groups of this initiative.
    Imágenes de mapeado óptico de dos corazones distintos de ratones que desarrollaron fibrilación ventricular.
    Research
    27 Nov 2023
    Nature Cardiovascular Research: Spanish scientists discover a promising therapeutic target for cardiac arrhythmias
    Representative results from participants showing atherosclerosis progression (left) and regression (disappearance of plaques, right) in arteries of the neck (carotids) and groin (femorals). Each image pair shows the results of the initial study at baseline and the follow-up study of the same artery 6 years later. The images show representative vascular ultrasound images on the right and 3-dimensional reconstructions on the left.
    Research
    20 Nov 2023
    JACC: Younger people are more vulnerable to the effects of cardiovascular risk associated with high blood cholesterol and hypertension

    Atherosclerosis, previously believed to be an irreversible progressive disease, can be reversed if risk factors are contolled early enough
    Research
    2 Oct 2023
    Diabetes Care: Obesity, high blood pressure, and lipid imbalance trigger a progressive loss of energy generation capacity in the heart

    Scientists at the CNIC have discovered that metabolic cardiovascular risk factors diminish the capacity of the heart to use glucose as an energy source
    la Dra. Mercedes Ricote y la Dra. Ana Paredes
    About the CNIC
    29 Sep 2023
    Researcher Ana Paredes wins the International Birnstiel Award 2023

    The Spanish National Centre for Cardiovascular Research (CNIC) researcher Dr Ana Paredes has won the International Birnstiel Award 2023
    The image represent glucose uptake in the brain measured by positron emission tomography in middle-aged individuals with low (top) or high (bottom) sustained cardiovascular risk over 5 years. The colors represent cerebral glucose consumption, with red indicating higher consumption and blue lower consumption
    Research
    31 Aug 2023
    The Lancet Healthy Longevity: Early action to control cardiovascular risk factors preserves brain metabolism

    A study published in The Lancet Healthy Longevity shows that brain metabolism, detected with advanced imaging techniques, declines more sharply in middle-aged people with a sustained high cardiovascular risk over 5 years
    Alejo Rodríguez-Fraticelli
    About the CNIC
    27 Jul 2023
    Alejo Rodríguez-Fraticelli: “The risk of cell therapies is not being able to do them fast enough in a scalable way”